Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma and social media: an uneasy marriage?

This article was originally published in Scrip

Executive Summary

Despite being the fastest growing marketing medium for many industries, social media channels present major legal and regulatory concerns for the pharma sector. Until the US FDA produces some guidance in this area later this year, pharma companies wanting to enter the fray have much to contemplate, explains Tim Worden.

You may also be interested in...



Pharmaceuticals and Social Media: An Uneasy Marriage?

Despite being the fastest growing marketing medium for many industries, social media channels present major legal and regulatory concerns for the pharmaceutical sector. Until the US Food and Drug Administration produces some guidance in this area later this year, pharma companies entering the fray have much to think about, explains Tim Worden.

UK Update: The New Model Clinical Investigation Agreement and the ABHI Code of Business Practice

Two recent developments in the UK – the implementation in the National Health Service of a model Clinical Investigation Agreement (mCIA)1,2 and a new code of business practice by the Association of British Healthcare Industries3 – represent significant changes to the legal and regulatory landscape for medical devices. The experience of the pharmaceutical industry under the model Clinical Trial Agreement (mCTA)4 and with the code of practice of the ABHI’s pharmaceutical counterpart, the ABPI, provides useful guidance on how to comply with, and utilise, these new additions to the medical devices framework.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel